Comment om “Validation and Modeling of Flow Cytometric CD36 Coefficient of Variation (CV) Analysis in the Diagnosis of Lower-Risk Myelodysplastic Syndromes”

The publication on "Validation and Modeling of Flow Cytometric CD36 Coefficient of Variation (CV) Analysis in the Diagnosis of Lower-Risk Myelodysplastic Syndromes.[1]" is interesting.This work presents strong empirical data on the function of the CD36 coefficient of variation (CV) in detecting red blood cell abnormalities and diagnosing myelodysplastic syndromes (MDS), particularly in low-risk patients.Although the mean CD36 CV value in MDS patients was higher than in controls, the difference was not statistically significant, suggesting the disease's biological variability, small sample size, or technical variations in measurement.However, the constant trend of elevated CD36 CV levels across patient groups suggests that this indicator has potential, especially when utilized in concert with other indicators rather than as a standalone diagnostic tool.The study found that combining the CD36 CV value with the Ogata score improved diagnostic specificity from 33.3% to 80% at a cutoff value of 3 points, with an AUC of 0.754.This supports the efficacy of MDS evaluation, especially in low-risk patients.A "multivariate" approach is required since bone marrow abnormalities in this patient population are frequently not severe enough to be recognized with a single parameter.However, the decreasing sensitivity with higher cutoffs indicates a trade-off between reducing false positives and the potential of missing diagnosis in patients with moderate anomalies, which physicians must weigh depending on the clinical situation.The study's main limitations include its retrospective nature and small sample size, which may impair the statistical power to detect variations in CD36 CV levels, particularly in low-risk MDS patients.Furthermore, applying a cutoff based on single-center data may limit its applicability to various clinical contexts because flow cytometry parameters vary depending on the device, parameter settings, and gating approaches.These variables could contribute to the statistical variability found.Overall, this study shows that CD36 CV can greatly improve the performance of current scoring systems, including the Ogata score, even though it is not a reliable diagnostic signal on its own.This illustrates a recent trend in the development of markers that give priority to anomalies in the red blood cell lineage.Comprehensive studies with higher sample numbers should be part of future research initiatives.The objectives of a multicenter study were to generate a uniform standardized CD36 CV score, incorporate additional erythroid dysplasia markers into multivariate models, and employ machine learning approaches to produce more precise prediction tools.The findings of this study provide a crucial foundation for future advancements in the use of flow cytometry in the diagnosis of low-risk and early-stage MDS.